PET and PET/CT using [ Detection is also limited by a considerable number of microcarcinomas that cannot be detected due to partial volume effects. Therefore small and in part rind-like tumours can often not be visualized. Furthermore, the differentiation between benign changes like prostatitis, high-grade intraepithelial neoplasia (HGPIN) or prostatic hyperplasia is not always possible. Therefore, at the present time, the routine use of PET/CT with [ 11 C]-and [ 18 F]-labelled choline derivates cannot be recommended as a first-line screening procedure for primary prostate cancer in men at risk. A potential application of choline PET and PET/CT may be to increase the detection rate of clinically suspected prostate cancer with multiple negative prostate biopsies, for example in preparation of a focused re-biopsy and may play a role in patient stratification with respect to primary surgery and radiation therapy in the future.
Introduction
Prostate cancer is currently the highest prevalent form of cancer in men (192, 280 cases, 25% of all incident cases) and the second most common cause of cancer associated deaths (9%) in the USA [1] [2] . The gold standard for diagnosing prostate cancer is histopathological examination of prostate tissue obtained by prostate needle biopsy. Commonly used diagnostic tools in the evaluation of prostate cancer are digital
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International Publisher rectal examination, measurement of serum levels of prostate specific antigen (PSA), transrectal ultrasound (TRUS) as well as TRUS-guided biopsies [2] . Beside these diagnostic modalities, morphological and functional imaging methods such as computed tomography (CT), magnetic resonance imaging (MRI), bone scintigraphy and positron emission tomography (PET, PET/CT) are also used.
Morphological imaging techniques such as TRUS, CT and MRI have demonstrated only limited accuracy for primary diagnosis of prostate cancer, recurrent disease as well as advanced disease. Concerning diagnosis of primary prostate cancer, CT has shown limited specificity. Furthermore the detection of lymph node metastases is limited by morphological imaging such as CT and MRI; first, small lymph node metastases cannot be visualized; second, size as only criterion might not be sufficient to detect metastatic involvement in lymph nodes. For the detection of bone metastases, CT may be of use in imaging trabecular changes caused by metastasis which appear relatively late in the course of bone metastases. Therefore increasing the diagnostic performance in prostate cancer imaging remains a major challenge. Combined molecular and morphological imaging techniques such as PET/CT may improve the diagnostic accuracy in imaging prostate cancer.
PET/CT based on increased glycolysis using [ 18 F]fluorodeoxyglucose (FDG) has shown only limited sensitivity for the detection of differentiated prostate carcinomas and imaging of recurrent prostate cancer in various studies [3] [4] [5] . Increased FDG uptake and accumulation is regularly only found in dedifferentiated, aggressive and metastasized prostate cancer. Other PET-and PET/CT tracers have been introduced for diagnosing prostate carcinoma based on an increased androgen receptor expression ([ 18 [12] . The use of choline for imaging prostate cancer is based on increased phosphorylcholine levels and an elevated phosphatidylcholine turnover in prostate cancer cells [13] [14] . After uptake into the tumor cell through a high affinity transporter system, choline is metabolized by choline kinase -which is the first step of the Kennedy pathway -and is incorporated into the phosphatidyl membrane. Key enzymes of the choline metabolism, like choline kinase, are up-regulated in prostate cancer cells [15] [16] . Additionally, an increased expression of choline transporters and an elevated choline transportation rate have been described [16] [17] [18] [19] .
The use of [ 11 C]-and [ 18 F]-labelled choline derivates for the detection of primary prostate cancer has been examined in many studies with conflicting results, for an overview see Souvatzoglou et al. [20] . While some studies with selected patient groups demonstrated high sensitivities for the detection of primary prostate cancer [21] [22] [23] , other studies reported lower detection rates [24] [25] [26] [27] [28] . Importantly the detection rate of primary prostate cancer using [ 11 C]-and [ 18 F]choline-PET/CT is influenced by the tumor configuration with small and partly `rind-like` carcinomas (onion ring form of growth) often not detected [28] . Furthermore, choline PET/CT has shown limited specificity.
This article reviews the use of PET and PET/CT using molecular imaging probes in prostate cancer with special emphasis on the use of radiolabeled choline derivates for diagnosis and staging of patients with primary prostate cancer.
Diagnosis of primary prostate cancer

CT
Morphological imaging techniques such as TRUS, CT and MRI have demonstrated only limited accuracy for diagnosis of primary prostate cancer. Regarding the diagnosis of primary prostate cancer, CT cannot differentiate benign from malignant prostatic tissue; therefore the specificity in differentiating malignant from benign prostatic lesions is limited [14] . For lymph node staging CT has also shown limited sensitivity (36% in a meta-analysis) [29] .
At present, CT imaging has no decisive role in the diagnosis of primary prostate cancer [30] . The use of CT imaging is recommended for patients at high risk with a PSA level > 20 ng/ml, Gleason score > 7 and/or clinical tumor stage T3 or higher [31] or for detection of lymph node metastases and lymph node staging [30] .
MRI
For detection, localization and definition of local extent of prostate cancer morphological and functional MRI techniques are increasingly being used. In T2-weighted MRI, prostate cancer tissue normally presents with a decreased signal intensity compared to the high signal intensity of the normal peripheral zone [30] . The detection rate of primary prostate cancer using MRI is superior compared to DRE and TRUS [32] . This result was corroborated by Hricak et al. (2007) who reported that MRI imaging performed better than CT, DRE and TRUS in the evaluation of uni-or bilateral disease of stage T2 and T4 [33] with sensitivity of 80% and specificity of 99% for detection of seminal vesicle invasion. Determination of the local tumor stage can be improved by using high resolution endorectal coil MRI [34] . Bloch et al. (2007) reported sensitivity between 75% and 89% for the determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MRI [35] . High resolution endorectal coil MRI is recommended for use as an additional imaging modality in patients with negative biopsy and suspected primary prostate cancer and patients with a medium or high probability of extraprostatic disease [36] .
Recent studies have evaluated functional and molecular MRI techniques for primary and nodal staging of prostate cancer such as diffusion weighted imaging (DWI) and dynamic-contrast-enhanced MRI as well as magnetic resonance spectroscopy (MRS). In some studies multiparametric MRI modalities were compared with choline PET/CT imaging.
Wefer et al. compared the accuracy of endorectal MRI and MRS with that of sextant biopsy for the sextant localization of prostate cancer. For sextant localization of prostate cancer, MRI and MRS were more sensitive but less specific than biopsy (67% and 76% versus 50%, and 69% and 68% versus 82%, respectively). The sensitivity of sextant biopsy was significantly lower in the prostate apex than in the mid prostate or prostate base (38% versus 52% and 62%, respectively). These results showed that MRI and MRS had an accuracy similar to biopsy for intraprostatic localization of cancer and that they were more accurate than biopsy in the prostate apex [37] . Mazaheri 11 C]choline PET/CT with whole-body MRI for staging prostate cancer. The authors reported sensitivity and specificity of 97% and 77%, respectively, for choline PET/CT and 79% and 94%, respectively, for whole-body MRI [40] .
The use of MRI with ultrasmall superparamagnetic iron oxide (USPIO) was reported to be significantly better than conventional MRI in differentiating benign from malignant lymph nodes and showed a high sensitivity in detection of prostate cancer lymph nodes [41] .
Eiber et al. showed the feasibility of using DWI for detection of lymph node metastases in patients with primary prostate and recurrent prostate cancer with a diagnostic accuracy of 85.6% [42] .
Beer et al. examined 14 prostate cancer patients with [ 11 C]choline PET/CT and DWI comparing the functional parameters SUV in PET and Apparent Diffusion Coefficient (ADC) in DWI of lymph nodes in prostate cancer using a linear regression analysis. ADC values and SUV showed a moderate but highly significant inverse correlation (r = -0.5144, p < 0.0001). In lymph nodes with low ADC values, the dispersion of SUV was more pronounced. Moreover, a highly significant difference was observed for mean ADC values and SUV in lymph nodes considered as benign or malignant by follow-up/histopathology (ADC 1.60 ± 0.24 vs. 1.09 ± 0.23 × 10(-3) mm(2)/s; SUV 1.82 ± 0.57 vs. 4.68 ± 03.12; p < 0.0001, respectively) [43] .
Based on the available literature, MRI imaging of prostate cancer is not routinely used in the diagnosis of primary prostate cancer at the present time. MRI can be useful for the evaluation of seminal vesicle infiltration and/or the diagnosis of extra-capsular spread with potential implications on staging and subsequent treatment. Furthermore, MRI may be useful as additional diagnostic tool in patients with multiple negative biopsies. In patients with high risk prostate cancer, an MRI (or CT) can be useful if the decision on the therapeutic strategy is under way.
FDG
The use of [ 18 F]fluorodeoxyglucose (FDG) in oncology is based on an increased glucose uptake in cancer cells by increased glucose transport through the cell membrane of malignant cells and an overexpression of the enzyme hexokinase. In the diagnosis of primary and metastatic prostate cancer, FDG PET/CT imaging has shown limited efficacy due to FDG uptake both in prostate cancer cells and benign prostatic tissue such as benign prostatic hyperplasia [44] [45] . Liu et al. (2001) and Hofer et al. (1999) showed a limited value for FDG-PET concerning differentiation of prostate hyperplasia, prostate carcinoma and local recurrence [3, 46] . Relatively low FDG uptake has been attributed to a relatively slow metabolic rate with a lower expression of glucose transport proteins of prostate cancer cells in comparison to other cancers.
There is a relationship between differentiation of prostate cancer cells and FDG uptake: low differentiated prostate cancer cells show higher FDG uptake in comparison to higher differentiated prostate cancer cells (Fig. 1 ). FDG shows renal excretion which leads to activity accumulation in the ureters and the bladder potentially obscuring the target organ and the adjacent tissues like seminal vesicles, hampering the detection of prostate cancer [47] . Oyama et al. (1999) reported a sensitivity of 64% in detection of primary prostate cancer with a tendency for higher FDG uptake in tumors with higher Gleason score [48] . This result was confirmed by Melchior et al. (1999) who reported higher FDG accumulation in poorly differentiated prostate cancer than in low grade prostate cancer [49] . Additionally, Jadvar et al. demonstrated that FDG uptake was higher in androgen-independent than androgen-sensitive human prostate cancer xenografts and androgen ablation caused a significant decrease in tumor FDG uptake of about 55% [50] , suggesting that higher FDG accumulation may not only be observed in androgen-independent tumors in comparison to androgen-sensitive tumors but also that androgen may also have a modulatory effect on the glucose metabolism of androgen-sensitive prostate cancer [45] . Schöder and Larson have summarized possible explanations for the poor performance of FDG PET/CT in primary diagnosis of prostate cancer: a relatively low metabolic rate, location of the prostate adjacent to the urinary bladder and lack of appropriate patient selection [51] . 
ACETATE
[ 11 C]acetate uptake in tumor cells is related to an enhanced lipid synthesis, reflecting the increased lipid synthesis during tumor growth of cancer cells [52] . An increase in fatty acid synthesis and an overexpression of the key enzyme fatty acid synthase have been demonstrated in prostate cancer cells [53] . In a comparative study by Oyama et [54] . However, [ 11 C]acetate is not a cancer-specific tracer and also accumulates in normal and hyperplastic tissue. Kato et al. (2002) showed that there was a significant overlap of uptake in normal prostate, benign prostate hyperplasia and prostate cancer [55] . Wachter et al. (2006) showed that combined PET/CT imaging or PET/MRI imaging may be helpful in defining the exact anatomical localization and classification of acetate PET findings [56] . A recent study showed a limited accuracy of 71% in the detection of prostate cancer and a lack of information on cancer aggressiveness using [ 11 C]acetate PET/CT [57] .
At the moment the use of [ 11 C]acetate PET/CT is not recommended in the diagnosis of primary prostate cancer. Fig. 2 and 3 ). The majority of reported sensitivities were based on a patient-based analysis, which showed better results (98-100%) than the lesion-based analysis. Some of the studies with a given selection of patient groups showed higher sensitivities for the detection of primary prostate cancer [21] [22] [23] , while other studies reported lower detection rates [24] [25] [26] [27] [28] .
METHIONINE
The following studies reported a high sensitivity for the detection of primary prostate cancer using PET and PET/CT with radioactively labelled choline derivates. [22] . These results showing high sensitivities of choline PET/CT for the detection of primary prostate cancer could not be confirmed by a significant number of studies that reported limited sensitivities for primary staging of prostate cancer. [26] .
PET/CT demonstrated a sensitivity of 83%, 66% and 4%, respectively, for localization of nodular lesions measuring more than 5 mm, for all lesions and lesions smaller than 5 mm, respectively. Logistic regression analysis revealed that only size had an influence on sensitivity. Based on sextant biopsy PET/CT had a slightly better sensitivity than transrectal ultrasound (66% vs. 61%, p=0.434). For determination of extraprostatic extension, sensitivity of PET/CT was low in comparison with MRI (22% vs. 63%, p=0.001) [26] . Giovacchini [24] , Scher et al. [27] and Martorana et al. [26] . Souvatzoglou et al. examined 43 patients with primary prostate cancer comparing imaging and histopathology using a segment-based analysis. They showed that the sensitivity of [ 11 C]choline PET/CT depends on the tumor configuration. Prostate segments involved by cancer could be identified in 79% of the patients using [ 11 C]choline PET/CT. Tumor configuration was the only factor significantly influencing tumour prediction (p<0.001) [28] .
Therefore there is emerging evidence as discussed by Souvatzoglou et al. that tumor configuration seems to be a major factor influencing the detection of primary prostate cancer. The detection of small and partly `rind-like` carcinomas (onion ring form of growth) is often not possible [28] .
Besides the limited sensitivity, the differentiation between benign prostatic hyperplasia (BPH), prostatitis or high-grade intraepithelial neoplasia (HGPIN) is not always possible in primary staging of prostate cancer using choline PET/CT [23-26, 66, 68-69] .
Reske et al. showed that choline uptake was significantly higher in prostate cancer in comparison to normal prostate tissue, prostatitis and other benign lesions (p<0.001). (SUVmean of benign prostatic lesion 2.0 +/-0.6; SUVmean of prostate cancer 3.5 +/-1.3). The authors reported a specificity of 87% using a SUVmax threshold of 2.65 [22] . Scher et al. reported a specificity of 61.9% (13/21) for the diagnosis of primary prostate cancer. The authors concluded that a differentiation between benign and malignant lesions is possible in most cases if imaging analysis is mainly based on qualitative criteria. The authors discussed a SUVmax cut-off of 3.3 for differentiation of benign and malignant lesions (with a sensitivity of 70.3% and a specificity of 57.1%) [27] . Kwee et al. reported a significant higher SUVmax in biopsy proven positive sextants compared to non-malignant sextans (mean value 5.5 vs. 3.3, p<0.001). Therefore the authors concluded that differentiation between benign and malignant prostatic lesions was possible using [ 18 F]choline PET. Kwee et al. (2006) also evaluated the efficacy of delayed [ 18 F]choline PET imaging or imaging at two time points for the localization of primary prostate carcinoma (7 minutes and 1 hour). The mean SUVmax for malignant findings significantly increased from 7.6 to 8.6 between early and delayed acquisition (mean retention index +14%, 95% confidence interval 6-22%, p = 0.002). The mean SUVmax for presumably benign lesions significantly decreased between the initial and the late image (4.8 to 3.9). The mean ratio between malignant and benign lesions increased significantly (1.4 to 1.8 in the late images (p = 0.0003)) [63] . Piert et al. examined 14 patients suffering from prostate cancer using [ 11 C]choline PET/CT. Tumor-to-background ratios Tmean /B-and Tmax/B-were calculated. Lesions with a Gleason score of 4+3 or higher showed significantly higher Tmean /B-and Tmax/B-ratios in comparison to the tumours with a Gleason score of 3+4 and lower. The authors also reported a correlation between MIB-1/Ki-67-expression, Gleason score and Tmean/B-and Tmax/B-ratios. Choline uptake correlated positively with the proliferation index [72] . Giovacchini et al. reported a specificity of 43% using a SUVmax cut-off of 2.5 for differentiation between benign and malignant prostatic lesions. The authors found the co-existence of prostatitis, HGPIN and BPH to be a main limitation of their study [25] . Schmid [68] . Martorana et al. showed that SUVmax was significantly higher in malignant lesions compared to benign lesion (p=0.027). However there was no statistically significant difference between false-positive and false-negative findings. Based on sextant biopsy, PET/CT had a slightly better sensitivity than transrectal ultrasound (66% vs. 61%, p= 0.434) but it was less specific (84% vs. 97%, p=0.008) [26] . Farsad et al. confirmed that benign entities such as HGPIN, prostatitis and BPH also show a high choline uptake. The authors reported a specificity of 81% for the detection of primary prostate cancer that was not significantly different from that with HGPIN [24] . Beheshti et al. examined 130 patients preoperatively using [ 18 F]fluorocholine (FCH) PET/CT. Differentiation between prostate cancer and prostatitis was not possible due to intense FCH accumulation of inflammatory lesions [59] . Souvatzoglou et al. confirmed the results concerning limited specificity of choline PET/CT in primary staging of prostate cancer. In their study there was no statistically significant difference between SUVmax of prostate cancer, benign prostate hyperplasia (p=0.102) or prostatitis (p=0.054) [28] .
In summary, choline PET/CT cannot be recommended as a first-line screening procedure for the diagnosis of primary prostate cancer in men at risk. It might play a role in the detection of clinically suspected prostate cancer with repeatedly negative prostate biopsies.
With respect to lymph node staging only a few studies reported results for sensitivity and specificity of choline PET/CT (see F]fluoride (FNa) PET/CT scanning for the detection of bone metastases from primary and recurrent prostate cancer. In the whole group of 38 patients (preoperatively as well as post-operatively) overall sensitivity, specificity and accuracy of PET/CT in the detection of bone metastases in prostate cancer were 74% , 99% and 85% for FCH and 81%, 93% and 86% for FNa, respectively. FCH PET/CT led to a change in the management in 2 of 38 patients due to the early detection of bone marrow metastases [73] .
In another study Beheshti et al. compared the uptake of FCH in bone metastases in 70 patients (32 preoperatively with biopsy-proven prostate cancer, 38 postoperatively with suspected recurrence of prostate cancer) in comparison to morphologic changes on CT. For all 70 patients (preoperatively as well as postoperatively) sensitivity, specificity and accuracy of FCH PET/CT in detecting bone metastases from prostate cancer were 79%, 97%, and 84%, respectively [74] .
In a prospective study Langsteger et al. compared the diagnostic performance of FCH and FNa for the detection of bone metastases in 42 patients with prostate cancer and a follow up of at least 6 months. Overall, bone involvement was present in 22 patients and absent in 18. For the whole group of patients (initial staging as well as patients referred for suspicion of recurrence), the patient-based diagnostic performance for FCH vs. FNa was 91% vs. 91% for sensitivity, 89% vs. 83% for specificity and 90% vs. 88% for accuracy (without statistically significant difference). There was also no significant difference in site-based diagnostic performance in the group of patients referred at initial staging. However, in the group of patients referred for suspicion of recurrence, FCH was significantly more specific than FNa (96% vs. 91%, P=0.033 with Obuchowski's correction) while sensitivity was the similar, 89% [75] .
Concerning M-staging of primary and recurrent prostate cancer FCH PET-CT may be superior for the early detection (i.e. bone marrow involvement and early cortical involvement) of metastatic bone disease. In patients with FCH-negative suspicious sclerotic lesions, a second bone-seeking agent (e.g. FNa) might give additional information.
Conclusion and Outlook
Choline PET/CT is a clinically valuable tool for re-staging patients with increasing PSA serum levels after definitive local therapy. However, at the present time choline PET/CT cannot be recommended as a first-line screening procedure for primary prostate cancer in men at risk due to its limited sensitivity, its dependency on tumor configuration and its limited specificity in differentiating prostate cancer tissue form benign pathologies. Choline PET/CT may be of value for the detection of clinically suspected prostate cancer with multiple negative prostate biopsies. Choline PET/CT plays a role in patient stratification with respect to lymph node involvement for primary surgery and radiation therapy. Therefore the potential role of choline PET/CT in lymph node staging of primary prostate cancer will have to be evaluated in further studies.
Although considerable progress has been made in the recent years with PET/CT using [ 11 C]-and [ 18 F]-labelled choline derivates, diagnostic performance still needs to be improved. Many strategies for prostate cancer imaging with novel radiotracers such as bombesin-based tracers or tracers for androgen receptor imaging are being assessed in preclinical studies and in some cases in first clinical feasibility studies. In the future more tumour-specific tracers may increase the sensitivity and specificity for multimodal imaging detection of prostate cancer. Advances in hybrid imaging, especially PET/MR, could also provide improvement in diagnostic accuracy by combining molecular imaging properties of PET with high resolution and excellent soft-tissue contrast of MRI.
